Patent intelligence · US
US 8716215
Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, o…
Patent details — US 8716215
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 6, 2014
- Expiration
- May 1, 2034
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Claims
- 38
- CPC classes
- A61K, A61K38/08, A61K38/1774, A61K38/1841
Quick answer
US 8716215 (Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease) is held by REGENERX BIOPHARMACEUTICALS, INC.. Status: granted. Granted May 6, 2014. Expires May 1, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 38
- CPC classes
- A61K, A61K38/08, A61K38/1774, A61K38/1841, A61K38/19, A61K38/191
More from REGENERX BIOPHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8716215?
US 8716215 (Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease) is held by REGENERX BIOPHARMACEUTICALS, INC.. Status: granted. Granted May 6, 2014. Expires May 1, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8716215?
REGENERX BIOPHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8716215 expire?
Our index shows an expiration date of May 1, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.